Endocrine disruptor mediated activation of PXR causes dyslipidemia
内分泌干扰物介导的 PXR 激活导致血脂异常
基本信息
- 批准号:9308696
- 负责人:
- 金额:$ 33.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-26 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAgonistAnimal ModelAnimalsApolipoprotein EArterial Fatty StreakAtherosclerosisCD36 AntigensCardiovascular DiseasesCause of DeathCellsChemical ExposureChemicalsChlorinated HydrocarbonsCholesterolChronicCitratesCosmeticsDevelopmentDiabetes MellitusDietDiseaseDoseDyslipidemiasEndocrine DisruptorsEnvironmentEnvironmental Risk FactorEtiologyExposure toFDA approvedFood PackagingFutureGene ExpressionGeneticGenetic TranscriptionGenetic VariationGoalsHealthHomeostasisHumanHyperlipidemiaIn VitroIndividualIntestinesKnowledgeLDL-Receptor Related Protein 1LinkLipidsLiverMediatingMedical DeviceModelingMolecularMorbidity - disease rateMusNuclear ReceptorsObesityOrganophosphatesPesticidesPharmaceutical PreparationsPharmacologic SubstancePilot ProjectsPlasmaPlasticizersPlayPolychlorinated BiphenylsReceptor ActivationRegulationResearchRisk AssessmentRoleTestingWild Type MouseXenobiotic MetabolismXenobioticsabsorptionanalogbisphenol Acardiovascular disorder riskcholesterol transportersdisorder riskenvironmental chemicalexperimental studygene environment interactionhuman diseasehumanized mousein vivointerestmortalitymouse modelnovelpackaging materialphthalatespregnane X receptorpublic health relevancereceptor functionsensortooluptake
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to investigate a novel mechanism linking exposure to endocrine disrupting chemicals (EDCs) with dyslipidemia and cardiovascular disease. The pregnane X receptor (PXR) is a nuclear receptor activated by numerous drugs, xenobiotic and dietary chemicals. Many EDCs activate PXR, including organochlorine and organophosphate pesticides, alkylphenols, phthalates, polychlorinated biphenyls, bisphenol A and its analogs. However, the role of PXR in mediating the pathophysiological effects of EDCs in humans and animals remains elusive. Mounting evidence implicates EDC exposure in the development of chronic human diseases but the contribution of these EDCs to the etiology of cardiovascular disease (CVD), obesity, and diabetes is poorly understood. We have recently revealed the pro-atherogenic effects of PXR in animal models and demonstrated that chronic PXR activation induces hyperlipidemia in wild-type mice and increases atherosclerosis in atherosclerosis-prone apolipoprotein E deficient (ApoE-/-) mice. Our central hypothesis is that EDCs which activate PXR will lead to hyperlipidemia and accelerated atherosclerosis in mice, thereby increasing the risk of CVD in exposed individuals. We propose the following specific aims to test this hypothesis: 1) What are the molecular mechanisms through which intestinal PXR activation induces hyperlipidemia? 2) How does exposure to FDA-approved phthalate substitute plasticizers elevate plasma lipid levels in mice? 3) Is EDC-mediated PXR activation necessary and sufficient to increase atherosclerosis development in ApoE-/- mice? Our research will establish the role of PXR in linking exposure to EDCs with hyperlipidemia and CVD, and will provide novel mechanistic links explaining how EDC exposure causes atherogenic effects. These studies are broadly translational and will provide strong evidence to inform future risk assessment for EDCs.
描述(由申请人提供):该项目的目的是研究一种与血脂异常和心血管疾病的内分泌破坏化学物质(EDC)联系起来的新型机制。妊娠X受体(PXR)是一种核受体,该核受体被许多药物,异种和饮食化学物质激活。许多EDC激活PXR,包括有机氯和有机磷酸盐农药,烷基苯酚,邻苯二甲酸盐,多氯联苯,双苯基A及其类似物。但是,PXR在介导EDC在人类和动物中的病理生理影响中的作用仍然难以捉摸。越来越多的证据表明,EDC在慢性人类疾病的发展中暴露,但这些EDC对心血管疾病(CVD),肥胖和糖尿病的病因的贡献知之甚少。我们最近揭示了PXR在动物模型中的促动脉粥样硬化作用,并证明慢性PXR激活诱导野生型小鼠中的高脂血症,并增加动脉粥样硬化的载脂蛋白E缺陷(APOE--/ - )小鼠的动脉粥样硬化。我们的中心假设是激活PXR的EDC将导致高脂血症并加速小鼠的动脉粥样硬化,从而增加暴露的个体CVD的风险。我们提出以下特定目的来检验这一假设:1)肠道PXR激活诱导高脂血症的分子机制是什么? 2)暴露于FDA批准的邻苯二甲酸酯替代化增塑剂如何提高小鼠的血浆脂质水平? 3)EDC介导的PXR激活是否需要且足以增加APOE - / - 小鼠的动脉粥样硬化发展?我们的研究将确定PXR在将EDC与高脂血症和CVD连接起来的作用,并将提供新的机械联系,以解释EDC暴露如何引起动脉粥样硬化作用。这些研究是广泛的转化,将提供有力的证据,以告知EDC的未来风险评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Changcheng Zhou其他文献
Changcheng Zhou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Changcheng Zhou', 18)}}的其他基金
Role of PXR in EDC-induced cardiovascular disease
PXR 在 EDC 诱发的心血管疾病中的作用
- 批准号:
10640665 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
10225373 - 财政年份:2018
- 资助金额:
$ 33.86万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
10458566 - 财政年份:2018
- 资助金额:
$ 33.86万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
9982358 - 财政年份:2018
- 资助金额:
$ 33.86万 - 项目类别:
Role of IKKβ in obesity and atherosclerosis
IKKβ 在肥胖和动脉粥样硬化中的作用
- 批准号:
10008480 - 财政年份:2016
- 资助金额:
$ 33.86万 - 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
- 批准号:
9109680 - 财政年份:2015
- 资助金额:
$ 33.86万 - 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
- 批准号:
9273599 - 财政年份:2015
- 资助金额:
$ 33.86万 - 项目类别:
Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
- 批准号:
8638093 - 财政年份:2014
- 资助金额:
$ 33.86万 - 项目类别:
Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
- 批准号:
8828205 - 财政年份:2014
- 资助金额:
$ 33.86万 - 项目类别:
Endocrine disruptor mediated activation of PXR causes dyslipidemia
内分泌干扰物介导的 PXR 激活导致血脂异常
- 批准号:
8743207 - 财政年份:2013
- 资助金额:
$ 33.86万 - 项目类别:
相似国自然基金
基因与家庭不利环境影响儿童反社会行为的表观遗传机制:一项追踪研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
不利地质结构对地下洞室群围岩地震响应影响研究
- 批准号:51009131
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
列车制动力对铁路桥梁的作用机理及最不利影响的研究
- 批准号:50178004
- 批准年份:2001
- 资助金额:23.0 万元
- 项目类别:面上项目
相似海外基金
The Role of Outpatient Diuretic Therapy in Bronchopulmonary Dysplasia
门诊利尿疗法在支气管肺发育不良中的作用
- 批准号:
10663469 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Integrated, Individualized, and Intelligent Prescribing (I3P) Clinical Trial Network
一体化、个体化、智能处方(I3P)临床试验网络
- 批准号:
10822651 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Supplement for Role of Environmental Weathering and Gastrointestinal Digestion on the Bioavailability and Toxicity of Microplastic and Cadmium Mixtures
补充环境风化和胃肠消化对微塑料和镉混合物的生物利用度和毒性的作用
- 批准号:
10854398 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别: